Materialise マネジメント
マネジメント 基準チェック /24
Materialiseの CEO はBrigitte de Vet-Veithenで、 Jan2024年に任命され、 の在任期間は 2.67年です。 は、会社の株式の0.047%を直接所有しており、その価値は$ 203.13K 。経営陣と取締役会の平均在任期間はそれぞれ2.7年と12年です。
主要情報
Brigitte de Vet-Veithen
最高経営責任者
n/a
報酬総額
| CEO給与比率 | n/a |
| CEO在任期間 | 2.7yrs |
| CEOの所有権 | 0.05% |
| 経営陣の平均在職期間 | 2.7yrs |
| 取締役会の平均在任期間 | 12yrs |
経営陣の近況
Recent updates
ナラティブ更新 • Sep 03
MTLS: Reaffirmed 2026 Guidance Will Support Higher Profitability Expectations
Analysts have modestly raised their price target on Materialise to about $8.06 from about $6.81, citing updated assumptions around discount rates, revenue growth, profit margins, and future P/E multiples. What's in the News for Materialise Materialise NV recorded impairment charges of €689,000 in the second quarter of 2026 related to tangible and intangible assets of RapidFit NV and Eyewear, following the transfer of these assets to their respective management teams.Seeking Alpha • Aug 31
Materialise: A High-Margin Medical Business Hiding In Plain Sight
Summary Materialise’s Medical continues to deliver double-digit growth and strong margins and is increasingly underpinning the company’s value. The Manufacturing segment is recovering, with aerospace strength offsetting weak prototyping demand and creating significant potential for margin expansion. Software is now an uncertainty, as recurring revenue growth has stalled despite Materialise's transition toward subscriptions and the introduction of new CO-AM products. The valuation remains attractive if Materialise can achieve even modest revenue growth and margin expansion over the next few years. Read the full article on Seeking Alpha分析記事 • Aug 30
Materialise NV (NASDAQ:MTLS) Released Earnings Last Week And Analysts Lifted Their Price Target To US$8.92
It's been a good week for Materialise NV ( NASDAQ:MTLS ) shareholders, because the company has just released its latest...
新しいナラティブ • Jun 01
Medical And Software Expansion Will Drive Stronger Margins And Earnings Durability
Catalysts About Materialise Materialise provides 3D printing software and services, with a particular focus on medical applications and industrial manufacturing. What are the underlying business or industry changes driving this perspective?新しいナラティブ • May 17
Cloud Software And Medical Constraints Will Pressure 3D Printing Adoption Yet Offer Gradual Upside
Catalysts About Materialise Materialise provides software and manufacturing solutions for 3D printing, with a particular focus on medical applications, industrial production and related services. What are the underlying business or industry changes driving this perspective?分析記事 • Nov 05
Materialise's (NASDAQ:MTLS) Sluggish Earnings Might Be Just The Beginning Of Its Problems
The market rallied behind Materialise NV's ( NASDAQ:MTLS ) stock, leading do a rise in the share price after its recent...分析記事 • Oct 06
Materialise NV's (NASDAQ:MTLS) P/E Is On The Mark
With a price-to-earnings (or "P/E") ratio of 54.9x Materialise NV ( NASDAQ:MTLS ) may be sending very bearish signals...分析記事 • Jul 27
Analyst Estimates: Here's What Brokers Think Of Materialise NV (NASDAQ:MTLS) After Its Second-Quarter Report
Shareholders might have noticed that Materialise NV ( NASDAQ:MTLS ) filed its quarterly result this time last week. The...分析記事 • Jul 25
Materialise (NASDAQ:MTLS) Is Looking To Continue Growing Its Returns On Capital
If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...分析記事 • May 04
After Leaping 28% Materialise NV (NASDAQ:MTLS) Shares Are Not Flying Under The Radar
Those holding Materialise NV ( NASDAQ:MTLS ) shares would be relieved that the share price has rebounded 28% in the...Seeking Alpha • Feb 24
Materialise: Manufacturing Headwinds Are A Distraction
Summary Materialise's share price dropped significantly after the company reported poor Q4 earnings, which were driven by European automotive market weakness. Despite recent challenges, Materialise's Medical segment continues to perform well and the transition of the Software segment to a subscription model is progressing. The Medical and Software segments are Materialise's primary value drivers and more than justify the company's current valuation. Issues with the Manufacturing segment may need to be resolved before the stock moves higher though. Read the full article on Seeking Alpha分析記事 • Feb 13
Materialise NV's (NASDAQ:MTLS) P/E Is Still On The Mark Following 26% Share Price Bounce
Materialise NV ( NASDAQ:MTLS ) shareholders have had their patience rewarded with a 26% share price jump in the last...
新しいナラティブ • Feb 09
Launch Of Mimics Flow And ACTech Expansion Will Advance Personalized Medicine
Focus on personalized medical solutions and enhanced platforms could drive revenue growth and improve operational efficiencies and net margins.分析記事 • Jan 31
Materialise NV (NASDAQ:MTLS) Shares Could Be 28% Above Their Intrinsic Value Estimate
Key Insights Using the 2 Stage Free Cash Flow to Equity, Materialise fair value estimate is US$6.77 Materialise is...分析記事 • Jan 07
These 4 Measures Indicate That Materialise (NASDAQ:MTLS) Is Using Debt Safely
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...分析記事 • Nov 07
Materialise NV's (NASDAQ:MTLS) 27% Jump Shows Its Popularity With Investors
Materialise NV ( NASDAQ:MTLS ) shares have had a really impressive month, gaining 27% after a shaky period beforehand...Seeking Alpha • Nov 04
Materialise: Strong Q3 Results Despite Ongoing Market Headwinds
Summary Materialise continues to grow on the back of its Medical segment, which is expanding at a rapid pace. Materialise's margins will continue to improve going forward, driven by a combination of revenue mix and economies of scale. The ACTech plant expansion will provide a material tailwind in 2025, although disruptions wrought by its startup are likely to negatively impact fourth quarter revenue. Despite the stock moving higher in recent weeks, Materialise remains deeply undervalued. Read the full article on Seeking Alpha分析記事 • Nov 01
Materialise's (NASDAQ:MTLS) Strong Earnings Are Of Good Quality
Materialise NV ( NASDAQ:MTLS ) recently posted some strong earnings, and the market responded positively. We did some...Seeking Alpha • Oct 25
Materialise: Medical Business Unit Is The Hidden Value
Summary Materialise NV is a Belgian additive manufacturing company, showing a 14.18% CAGR in its Medical segment from FY18 to FY23. Despite mixed results in other segments, Materialise maintains profitability with positive FCF and a strong balance sheet, supported by €63 million in net cash. The company's strategic positioning in high-value sectors and steady growth, combined with a net cash position and positive FCF, highlight its upside potential. DCF analysis suggests Materialise is undervalued by 35-40%, justifying a "buy" rating due to its innovative edge and expanding market in healthcare. Read the full article on Seeking Alpha分析記事 • Oct 25
Is There Now An Opportunity In Materialise NV (NASDAQ:MTLS)?
While Materialise NV ( NASDAQ:MTLS ) might not have the largest market cap around , it led the NASDAQGS gainers with a...Seeking Alpha • Aug 01
Materialise Stock: Nearing An Inflection Point (Rating Upgrade)
Summary Materialise NV continues to face headwinds from soft prototyping demand and muted 3D printer sales. Despite this, Materialise reported solid Q2 results, with growth improving sharply. Recent acquisitions, new software launches, and expanded manufacturing capacity are expected to drive growth going forward. While Materialise's share price has moved higher recently, the prospect of solid growth and significantly higher margins are not priced into the stock. Read the full article on Seeking Alpha分析記事 • Aug 01
The Return Trends At Materialise (NASDAQ:MTLS) Look Promising
Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...Seeking Alpha • Apr 26
Materialise Q1: Progress Against Headwinds
Summary Materialise NV faces a challenging demand environment and is transitioning to a cloud-based SaaS business model, impacting its financial performance. The software business is progressing slowly, while the medical business continues to perform well. The manufacturing business is struggling, but the startup of the expanded ACTech facility later in the year could change this. Macro headwinds and ongoing investments probably limit near-term upside. Longer term, Materialise appears deeply undervalued. Read the full article on Seeking Alpha分析記事 • Apr 19
Materialise's (NASDAQ:MTLS) Strong Earnings Are Of Good Quality
Materialise NV ( NASDAQ:MTLS ) just reported healthy earnings but the stock price didn't move much. Investors are...Seeking Alpha • Feb 26
Materialise: Upside From A Transition To Profitability
Summary The demand environment continues to weigh on Materialise's business, although the Medical segment remains a standout, with strong growth and improving margins. The adoption of robotics in joint replacement surgeries poses a threat to Materialise's medical business, though. Investments in the CO-AM platform and the ACTech facility expansion should begin to pay off in 2024, supporting growth and Materialise's competitive position. Given Materialise's relatively low valuation and the potential for solid growth and improving margins, Materialise's stock should do well over the next 1-2 years. Read the full article on Seeking Alpha分析記事 • Feb 23
Does Materialise (NASDAQ:MTLS) Have A Healthy Balance Sheet?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Seeking Alpha • Jan 31
Materialise NV: Consolidation And New Developments To Emerge As A Rising Star In The Additive Manufacturing Industry
Summary Materialise NV currently exhibits better growth, margins and fundamentals than its main competitors, positioning itself well in an industry that is estimated to grow at a CAGR of 16% until 2032; The medical business unit (c.a. 38.5% of total revenues in 9M23) continues to achieve double-digit growth, with the appointment of the new CEO to focus strongly on this segment; Both the analysis of multiples and DCF here presented show that the current share valuation is 40-45% below its fundamental value. Read the full article on Seeking Alpha分析記事 • Jun 14
Here's Why Materialise (NASDAQ:MTLS) Can Manage Its Debt Responsibly
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...分析記事 • May 23
Returns On Capital At Materialise (NASDAQ:MTLS) Paint A Concerning Picture
Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Ideally, a business...CEO
Brigitte de Vet-Veithen (54 yo)
2.7yrs
在職期間
Mrs. Brigitte de Vet-Veithen is Chief Executive Officer of Materialise NV from January 01, 2024 and joined Materialise NV in 2016. Mrs. de Vet-Veithen was Executive Vice President of Materialise Medical of...
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| Founder & Chairman | 36.2yrs | データなし | 0.28% $ 1.2m | |
| Chief Executive Officer | 2.7yrs | データなし | 0.047% $ 203.1k | |
| Chief Financial Officer | 3.3yrs | データなし | データなし | |
| Executive VP & COO | no data | データなし | 0.26% $ 1.1m | |
| Chief Strategy & Technology Officer and Executive VP | 10.7yrs | データなし | 0.24% $ 1.0m | |
| Executive Vice President | 27yrs | データなし | 0.13% $ 548.7k | |
| Interim HR Director & CHRO | 1.3yrs | データなし | データなし | |
| Executive Vice President of Manufacturing | 2.7yrs | データなし | 0.076% $ 329.9k | |
| Executive Vice President of Software | 2.7yrs | データなし | データなし | |
| Executive Vice President of Medical | 1.7yrs | データなし | データなし |
2.7yrs
平均在職期間
54yo
平均年齢
経験豊富な経営陣: MTLSの経営陣は 経験豊富 であると考えられます ( 2.7年の平均在職年数)。
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| Founder & Chairman | 36.2yrs | データなし | 0.28% $ 1.2m | |
| Independent Director | 9.3yrs | €11.00k | データなし | |
| Independent Director | 12.8yrs | €11.00k | 0.31% $ 1.3m | |
| Independent Director | 20.2yrs | €11.00k | データなし | |
| Director | 13.7yrs | €11.00k | 0.54% $ 2.3m | |
| Independent Director | 7.8yrs | €11.00k | 0.010% $ 43.9k | |
| Director | 28.8yrs | データなし | 0.28% $ 1.2m | |
| Independent Director | 11.3yrs | €11.00k | 0.0049% $ 21.2k | |
| Director | 6.7yrs | €11.00k | データなし | |
| Director | 1.7yrs | データなし | データなし |
12.0yrs
平均在職期間
61yo
平均年齢
経験豊富なボード: MTLSの 取締役会 は経験豊富で 経験豊富 です ( 12年の平均在任期間)。
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/09/10 10:42 |
| 終値 | 2026/09/10 00:00 |
| 収益 | 2026/06/30 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した ご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Materialise NV 3 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。11
| アナリスト | 機関 |
|---|---|
| John Baliotti | Brean Capital Historical (Janney Montgomery) |
| Robert Burleson | Canaccord Genuity |
| Troy Jensen | Cantor Fitzgerald & Co. |